Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab, HAIC, and Targeted Therapy for Advanced Colorectal Cancer Liver Metastasis
NCT06199232Completed
- Sponsor
- Peking University
- Start
- Jan 2024
- Primary completion
- Jul 2026
- Modality
- Fragment-Derived Small Molecules, Monoclonal Antibodies, Orthosteric Ligands
- Countries
- 1
01
Overview
Open-label, single-arm trial of tislelizumab, KL-140 and fruquintinib in colorectal cancer (CRC), sponsored by Peking University. Primary endpoint: Progression-Free Survival rate at 6 months. Started Jan 2024; status: completed.
02
Drugs
tislelizumabKL-140fruquintinib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06199232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06199232.